Coagulopathy, Blood Loss, and Vascular Endothelial Growth Factor in Advanced Epithelial Ovarian Cancer

2006 ◽  
Vol 107 (Supplement) ◽  
pp. 107S
Author(s):  
John P. Geisler ◽  
Georgiann C. Linnemeier ◽  
Michael C. Wiemann ◽  
John Broshears ◽  
Greg A. Miller ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Blood Loss ◽  
Epithelial Ovarian Cancer ◽  
Vascular Endothelial ◽  
Advanced Epithelial Ovarian Cancer ◽  
Endothelial Growth Factor

Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor

2004 ◽  
Vol 14 (1) ◽  
pp. 82-88
Author(s):  
M. SÖNMEZER ◽  
M. GÜNGÖR ◽  
A. Ensari ◽  
F. Ortaç
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Epithelial Ovarian Cancer ◽  
Transforming Growth Factor ◽  
Prognostic Significance ◽  
Transforming Growth Factor Β ◽  
Vascular Endothelial ◽  
Clinicopathologic Factors ◽  
Endothelial Growth Factor

We aimed to evaluate the prognostic significance of microvessel density (MVD), vascular endothelial growth factor (VEGF), and transforming growth factor β (TGFβ), as well as to find out the relationship between MVD, and VEGF and TGFβ in epithelial ovarian cancer (EOC). Surgical specimens of 47 patients with stage I–IV primary EOC, who underwent extended surgical staging according to FIGO, were investigated. Five-μm thick tissue sections were immunostained with antibody to factor VIII-related antigen, and MVD was assessed at three separate areas of ×200 magnification. Expressions for VEGF and TGFβ were evaluated by immunohistochemical staining using related monoclonal antibodies. Results were correlated with clinicopathologic factors and survival. We did not find any correlation between MVD and clinicopathologic factors, or patient survival. Similarly, there was no association between the degree of VEGF staining and survival or clinicopathologic factors, except preoperative ascites volume, which was higher in patients showing moderate and intense VEGF staining than those with weak VEGF staining (P = 0.052). The expression of TGFβ was inversely correlated with preoperative CA-125 levels (P < 0.05). Furthermore, there was no correlation between MVD and the staining intensity of VEGF or TGFβ. In conclusion, angiogenesis does not appear as a prognostic factor in EOC. We suggest that VEGF is an important mediator of ascites formation, and that TGFβ, which is supposed to have tissue-specific actions in tumorigenesis, may have growth-inhibitory functions in EOC.

scholarly journals Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer

2017 ◽  
Vol 27 (7) ◽  
pp. 1325-1332 ◽  
Author(s):  
Hiroaki Komatsu ◽  
Tetsuro Oishi ◽  
Hiroaki Itamochi ◽  
Muneaki Shimada ◽  
Shinya Sato ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Protein Expression ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Biomarker ◽  
Stage I ◽  
Stage Iii ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

BackgroundBevacizumab, which targets vascular endothelial growth factor (VEGF)-A, has recently been proven to be effective for the treatment of epithelial ovarian cancer (EOC). Thus, interest in VEGF-A has increased. There are few reports on concomitant detection of both ligands and its soluble receptors in serum samples, and the significance of serum VEGF-A in EOC is unclear, unlike the situation with tissue samples. We conducted the present study to explore the levels of serum VEGF family and its receptors and to evaluate their utility as prognostic biomarkers.MethodsA total of 128 patients with EOC, who were consecutively treated at Tottori University Hospital between 2006 and 2012, were included. Blood samples were collected before initial surgery. Serum concentrations of VEGF-A, VEGF-C, VEGFR-1, and VEGFR-2 were analyzed by enzyme-linked immunosorbent assay. We also examined the mRNA and protein expression of VEGF-A in tumor tissue from 30 cases by real-time reverse transcription polymerase chain reaction and immunohistochemistry.ResultsThe levels of VEGF-A in patients with stage III/IV disease were significantly higher than those with stage I/II disease (P = 0.0036). On the other hand, the level of VEGFR-2 in stage III/IV was significantly lower than that in stage I/II (P = 0.0026). With the cutoff value of VEGF/VEGFRs at the median level, the overall survival (OS) for patients with high VEGF-A levels was significantly lower than those with low levels (P = 0.015). Patients with high VEGFR-2 levels showed better prognosis than those with low VEGFR-2 levels (P = 0.023). Multivariate analysis revealed that International Federation of Gynecology and Obstetrics stage and serum VEGF-A were independent prognostic factors for OS [hazard ratio 2.01, 95% confidence interval (1.13–3.63), P = 0.017]. There was no significant correlation between mRNA or protein expression and serum levels of VEGF-A.ConclusionsSerum VEGF-A is an independent prognostic factor for OS in patients with EOC, implying that serum VEGF-A is a prognostic biomarker for EOC. Further study to validate the data is needed.

Association of Vascular Endothelial Growth Factor Gene Polymorphisms With Susceptibility to Epithelial Ovarian Cancer

2010 ◽  
Vol 20 (5) ◽  
pp. 717-723 ◽  
Author(s):  
Yan Li ◽  
Yan Wang ◽  
Shan Kang ◽  
Na Wang ◽  
Rong-Miao Zhou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Confidence Interval ◽  
Epithelial Ovarian Cancer ◽  
Odds Ratio ◽  
Gene Polymorphisms ◽  
Angiogenic Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Background:Vascular endothelial growth factor (VEGF) is a major angiogenic factor involved in a number of pathological processes, including neovascularization, a crucial step in the development of solid malignancies. The aim of this study was to investigate the association of polymorphisms in the VEGF gene with susceptibility to epithelial ovarian cancer (EOC).Methods:This case-control study included 303 EOC patients and 303 healthy controls. Genotyping of the VEGF gene polymorphisms at −460C/T, −1154G/A, −2578C/A, and +936C/T were performed by polymerase chain reaction and restriction fragment length polymorphism analysis.Results:No significant difference was found in allele and genotype distributions of the −460C/T, +936C/T, and −2578C/A polymorphisms between patients and controls. However, the frequencies of −1154G/A genotype and allele were significantly different between the two groups (P = 0.037, P = 0.013). Compared with the G/A + A/A genotype, the G/G genotype could significantly increase the risk of developing EOC (odds ratio, 1.64; 95% confidence interval, 1.12-2.39). The haplotype analysis suggested that the −460T/−1154A/−2578C haplotype exhibited a decrease in the risk of developing EOC compared with the −460T/−1154G/−2578C haplotype (odds ratio, 0.644; 95% confidence interval, 0.415-0.999).Conclusions:The study suggested a possible association between the VEGF −1154G/A polymorphism with susceptibility to EOC, but there is no support for an association of the VEGF −460C/T, +936C/T, and −2578C/A polymorphisms with the risk for EOC.

Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer

2004 ◽  
Vol 93 (1) ◽  
pp. 215-222 ◽  
Author(s):  
Kohkichi Hata ◽  
Kentaro Nakayama ◽  
Ritsuto Fujiwaki ◽  
Hidetaka Katabuchi ◽  
Hitoshi Okamura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Epithelial Ovarian Cancer ◽  
Vascular Endothelial ◽  
Factor Gene ◽  
Growth Factor Gene ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document